97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details
臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-004002-25-IT (EUCTR) | 24/10/2019 | 17/06/2021 | A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis | A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis - QUASAR | Moderately to Severely Active Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: GUSELKUMAB Product Code: [CNTO1959] INN or Proposed INN: GUSELKUMAB Other descriptive name: * D.3.4 Solution for infusion in pre-filled syringe Product Name: GUSELKUMAB Product Code: [CNTO1959] INN or Proposed INN: GUSELKUMAB Other descriptive name: * D.3.4 Solution for infusion in pre-filled syringe Product Name: GUSELKUMAB Product Code: [CNTO1959] INN or Proposed INN: Guselkumab Other descriptive name: * D.3.4 Solution for injection/infusion in pre-filled syringe Product Name: GUSELKUMAB Product Code: [CNTO1959] INN or Proposed INN: GUSELKUMAB Other descriptive name: * D.3.4 Solution for injection in pre-filled syringe | JANSSEN CILAG INTERNATIONAL NV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 950 | Phase 3 | United States;Bulgaria;Germany;Japan;Sweden;Poland;Belgium;Argentina;Canada;Hungary;United Kingdom;Turkey;Czechia;Korea, Republic of;China;Netherlands;Latvia;Australia;Malaysia;France;Italy;Israel;Russian Federation;Ukraine;Spain;Slovakia;Hong Kong;Taiwan;Portugal |